After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer.
Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer.
The CALGB 50904 trial tested the addition of bortezomib to ofatumumab and bendamustine in patients with previously untreated high-risk follicular lymphoma.
A same-day biopsy program for women helped reduce disparities related to age, race, and insurance type in breast cancer care.
A phase I/II trial tested the combination of niraparib and pembrolizumab in patients with recurrent ovarian carcinoma.
A Mayo Clinic study tested metformin, believed to have anti-lymphoma activity, among patients with newly diagnosed diffuse large B-cell lymphoma or follicular lymphoma.
Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia.
Researchers tested the MET inhibitor capmatinib in patients with non–small-cell lung cancer and a MET exon 14 skipping mutation.
Researchers conducted a cost-effectiveness analysis on the two FDA-approved CAR T-cell therapies for diffuse large B-cell lymphoma.
Lurbinectedin may represent a new treatment option as second-line therapy for patients with small-cell lung cancer.